JB 991

Drug Profile

JB 991

Alternative Names: JB991

Latest Information Update: 23 Feb 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synphora
  • Developer Swedish Orphan Biovitrum; Synphora
  • Class Anti-inflammatories; Prostaglandins; Skin disorder therapies
  • Mechanism of Action Apoptosis stimulants; Prostaglandin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glaucoma; Psoriasis

Most Recent Events

  • 23 Feb 2010 No development reported - Phase-II for Psoriasis in Sweden (Topical)
  • 23 Feb 2010 No development reported - Preclinical for Glaucoma in Sweden (Topical)
  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top